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Article Synopsis:  
Enforcement action against pharmacists is most prevalent when pharmacists fail to exercise 
corresponding responsibility. This cross-sectional study examined the relationship between 
pharmacists’ use of Indiana’s PDMP and dispensing practices of controlled substance prescriptions 
(CSP). Changes in dispensing, to dispense fewer CSPs, were attributed to PDMPs increasing 
access to patient drug histories by 53% of pharmacists. The study found that PDMP users were 
more likely to report refusing to dispense a CSP. Consistent use of PDMPs in pharmacy practice 
leads to more refusals of CSPs. Increased access to patient information facilitates pharmacists’ 
ability to detect prescription drug abuse and diversion. 
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ABSTRACT 1 
BACKGROUND: Pharmacists have shared responsibility to investigate the validity of controlled 2 
substance prescriptions (CSPs) that raise red flags and subsequently exercise their right to refuse 3 
to dispense a CSP if its validity cannot be verified.  Improving access to clinical practice tools, 4 
such as prescription drug monitoring programs (PDMPs), may increase availability of a patient’s 5 
drug history, which is critical to making informed clinical decisions about dispensing CSPs.  6 
OBJECTIVES: The purpose of this study was to examine how integration and consistent use of a 7 
PDMP in pharmacy practice impacts pharmacists’ dispensing practices related to CSPs.  8 
METHODS: A cross-sectional study examined pharmacists’ knowledge and use of Indiana’s 9 
PDMP (INSPECT) and dispensing practices of CSPs. Three outcome measures were analyzed 10 
using multiple logistic regression in order to examine the relationship between PDMP use and 11 
pharmacists’ controlled substance dispensing behaviors.   12 
RESULTS: Pharmacists were 6.4 times more likely to change their dispensing practice to dispense 13 
fewer CSPs if they reported INSPECT provided increased access to patient information. 14 
Pharmacists who always use INSPECT refused an average of 25 CSPs annually compared to an 15 
average of 7 refusals for pharmacists not using INSPECT.  Pharmacists using INSEPCT 16 
consistently (at every visit) were 3.3 times more likely to refuse to dispense more CSPs than 17 
pharmacists who report never using INSPECT.  18 
CONCLUSION: Integration of PDMPs in pharmacy practice may improve a pharmacist’s ability 19 
to make informed clinical decisions and exercise sound professional judgment.  Providing 20 
clinical practice tools to both prescribers and pharmacists is important to preventing drug 21 
diversion and prescription drug abuse in the United States. Future research should focus on 22 
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understanding the barriers and challenges to successful integration of PDMPs in pharmacy 23 
practice. 24 
INTRODUCTION 25 
In 2015, the Center for Disease Control and Prevention (CDC) reported that drug deaths 26 
related to prescription opioids have remained stable since 2012.  This may suggest that the 27 
United States is gaining some ground in regards to fighting the epidemic of nonmedical use of 28 
prescription drugs.  However, there remains a significant amount of work to be done to improve 29 
the prevention and treatment of substance abuse.1 In 2007, the CDC reported that every 19 30 
minutes someone dies from an unintentional prescription drug overdose in the United States, 31 
which resulted in 27,000 deaths in 2007 alone.2  If the number of deaths related to prescription 32 
drug abuse is not alarming enough, the CDC reports that for every unintentional overdose, “9 33 
persons are admitted for substance abuse treatment, 35 visit emergency departments, 161 report 34 
drug abuse or dependence, and 461 report nonmedical uses of opioid analgesics”.2  Prescription 35 
drug abuse is by no means a new problem in the United States.  However, the continued growth 36 
and the current scale of the problem has reason to raise serious concern.3  The distribution of 37 
opioid drugs has increased by over 7 times between 1997 and 2007.2  Unfortunately, with this 38 
increase in distribution of opioid drugs comes an increased risk of drug diversion.  Drug 39 
diversion occurs when prescription drugs are used for recreational purposes, and thus are 40 
“diverted” from their original purpose.4, 5  Although, drug diversion can occur at various stages 41 
of the prescribing and dispensing process, the pharmacist may be the “last line of defense”.4, 5  42 
Federal regulation 21 C.F.R. § 1306 requires that prescriptions for controlled substances 43 
be issued for legitimate medical purposes by individual practitioners acting in the usual course of 44 
their professional practice.4, 5 That same law imposes responsibility on pharmacists who fill the 45 
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prescriptions. If pharmacists knowingly fill improper or invalid prescriptions, they, as well as the 46 
prescribers, can be held accountable.5, 6 Similarly, state law requires pharmacists performing 47 
their duties to exercise professional judgment that is in the best interest of their patients’ health. 48 
Before honoring prescriptions, pharmacists are required to take reasonable steps to determine 49 
whether a prescription has been issued in compliance with state law.4 According to federal 50 
regulation 21 C.F.R. § 1306, a pharmacist may refuse to fill a prescription if professional 51 
judgment suggests filling it would be contrary to law, be against the best interest of the patient, 52 
aid or abet an addiction or habit, or be contrary to the health and safety of the patient.4  53 
Unfortunately, making a clinical decision to refuse to dispense a controlled substance may prove 54 
difficult for many pharmacists due to a variety of factors that block or inhibit their ability to 55 
make an evidence-based clinical decision such as lack of patient information or lack of evidence-56 
based resources.7 57 
In recent decades, Prescription Drug Monitoring Programs (PDMPs) have become more 58 
prominent across the United States.  A PDMP is a statewide electronic database that collects 59 
detailed data on controlled substance prescriptions (CSPs) in a state. 8, 9  As of 2013, 49 states 60 
had enacted legislation to develop PDMPs, and 48 states have implemented these programs.8  61 
PDMPs can help identify major sources of prescription drug diversion such as prescription fraud, 62 
forgeries, doctor shopping and improper prescribing and dispensing practices.10  PDMPs have 63 
proven to be invaluable tools in fighting the growing prescription drug abuse epidemic in the 64 
United States by reducing drug diversion of controlled substances and improving clinical 65 
decision-making through increased access to detailed patient drug histories for both prescribers 66 
and dispensers.10  67 
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In 2004, the State of Indiana expanded previous legislation and secured grant funding to 68 
establish the Indiana Scheduled Prescription Electronic Collection and Tracking Program 69 
(INSPECT), Indiana’s PDMP, in order to provide an additional clinical resource to ultimately 70 
improve providers’ clinical-decisions by expanding access to their patients prescription drug 71 
histories. An INSPECT report summarizes all CSPs a patient has been prescribed and includes 72 
information regarding the practitioner(s) who prescribed the controlled substance as well as the 73 
pharmacy and pharmacist who dispensed the CSP.11   Although, a growing body of evidence 74 
suggests that incorporation of PDMPs are effective in increasing clinical-decision making by 75 
providing greater access to patient drug information, nearly 30% of providers in Indiana report 76 
not using INSPECT, according to a 2012 study conducted by the Indiana University Center for 77 
Health Policy (CHP).10, 12  While Indiana pharmacists were significantly more likely to have 78 
heard of INSPECT they, unfortunately, were not more likely to have reported using the program 79 
in their pharmacy practice.12 80 
Pharmacists may be considered the “gatekeepers” of the controlled substances that have 81 
had such an impact on the prescription drug abuse epidemic in the U.S. As the “last line of 82 
defense,” pharmacists are challenged with ensuring that patients being treated for legitimate 83 
chronic pain have access to their CSPs, while identifying CSPs that have not been prescribed for 84 
a valid medical purpose.8  Furthermore, pharmacists have the responsibility to investigate the 85 
validity of CSPs that raise red flags, resolve these red flags, and ultimately exercise their right to 86 
refuse to dispense a CSP if the validity of the prescription cannot be verified.   87 
PDMPs are valuable clinical resources that provide pharmacists with additional 88 
information regarding their patients.  This increased access to patient data facilitates pharmacists 89 
ability to detect prescription drug abuse and diversion.13  In a study conducted by Fleming et al., 90 
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pharmacists were prompted to use a PDMP in order to confirm suspicions of forgery related to 91 
CSPs.13 Another study examined variations in pharmacy practice between users and non-users of 92 
PDMPs. This study suggested that PDMP users were less likely to discuss concerns of suspicion 93 
of drug diversion with the patient, but were as likely to contact the provider, refer the patient 94 
back to the provider, and refuse to fill the prescription.14   The results from these two studies 95 
suggest that utilization of PDMP data to investigate CSPs when there is a question to their 96 
validity may increase a pharmacists level of confidence to take action and to exercise 97 
corresponding responsibility.13 98 
The purpose of this study is to examine how integration and consistent use of a PDMP in 99 
pharmacy practice impacts pharmacists’ dispensing practices related to CSPs. The study aims to 100 
determine if the use of INSPECT as a clinical resource in pharmacy practice: (1) promotes a 101 
change in practice to dispense fewer CSPs, (2) increases the likelihood of a pharmacist to report 102 
having refused to dispense a CSP, (3) and whether and to what extent more consistent use of 103 
INSPECT influences a pharmacist’s total annual refusals of CSPs.  As more and more evidence 104 
suggests that PDMPs are effective in reducing drug diversion and improving clinical decision-105 
making, it is believed that pharmacists who report more consistent use of INSPECT in their 106 
pharmacy practice will be more likely to refuse dispensation of  CSPs as a result of increased 107 
access to patient information that provides the data necessary to support their professional 108 
judgment.10 109 
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METHODS 110 
Study Design 111 
Survey & Data Collection 112 
The study population included 10,606 providers who were identified by the IPLA as a 113 
pharmacist in the State of Indiana who held a valid license to dispense controlled substances in 114 
2012. This cross-sectional study examined survey data collected from Indiana pharmacists 115 
through the IPLA INSPECT Knowledge and Use Survey.12  The survey was developed through a 116 
collaborative effort between representatives from IPLA, the Indiana State Prescription Drug 117 
Abuse Prevention Task Force Education Committee, and the Indiana University Purdue 118 
University – Indianapolis (IUPUI) Center for Health Policy (CHP). The web-based survey was 119 
designed to gather information on pharmacists’ practice characteristics and behaviors as well as 120 
key information about their knowledge and use of INSPECT. At the request of the CHP, IPLA 121 
sent an initial electronic invitation to all eligible practitioners as well as 3 follow-up reminders to 122 
complete the survey. The study was sanctioned by the Indiana Board of Pharmacy, and the study 123 
design and methods was reviewed and approved by Indiana University Institutional Review 124 
Board. 125 
Of the 10,606 eligible pharmacists, a total of 1,582 completed the survey yielding an 126 
overall response rate of 15%.  Due to the relatively low response rate for this survey, basic 127 
demographics of the study sample were compared to Indiana’s 2012 Pharmacist Workforce Data 128 
to ensure the sample was representative of Indiana’s total pharmacist population.15  Table 3 129 
illustrates the demographic characteristics for both the study sample and Indiana’s pharmacist 130 
workforce in 2012.  The table also includes other demographic and practice characteristics 131 
collected from the survey, which are relevant to this study. The sample exhibited similar 132 
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characteristics to Indiana’s 2012 Pharmacist workforce in regards to age, years practicing, and 133 
gender.   134 
Study Variables 135 
The study contained 3 primary outcome measures, which include (1) dispensation 136 
change, (2) refused dispensations, (3) and annual refusals.  Operational definitions for the 137 
outcome measures are included in Table 1. Contextually relevant demographic and practice 138 
characteristics were included in all analysis as covariates to control for factors that may influence 139 
the relationship between the primary outcome measure and the dependent variable.   140 
One important practice characteristic that is commonly included in pharmacy research is 141 
degree type (PharmD, MPharm, BPharm). This measure is typically included to control for 142 
variations in education and training that may influence pharmacists’ attitudes beliefs, practice 143 
characteristics as well as clinical knowledge.  Degree type was not available in the data for this 144 
study. Instead, a new variable, training period, was generated to capture the important 145 
characteristics associated with variations in professional training. Training period is a 3 level 146 
categorical variable that indicates at what period in time the pharmacist went through training 147 
and was calculated based on the number of years in professional practice. Pharmacists practicing 148 
today were trained in one of three distinct cohorts, which are bound by events relating to the 149 
adoption of the Doctorate of Pharmacy as the sole entry degree for the profession.  The 150 
parameters for training period are described in Table 2. Training period was incorporated as a 151 
covariate in all the statistical models for this study in order to control for variations in education 152 
and training. 153 
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Data Analyses 154 
All statistical analyses were performed using SAS Statistical Software 9.4©. The 3 155 
outcome variables were assessed with determination of odds ratio (OR) estimates and 95% Wald 156 
confidence intervals (CIs). Descriptive statistics (frequencies, means, and standard deviations) 157 
were performed when appropriate.  Practice and demographic characteristics as well various 158 
independent response variables were analyzed using independent samples t tests or one-way 159 
analysis of variance (ANOVA).  160 
Multiple Logistic Regression 161 
In order to perform a binary logistic regression, the outcome measure dispensation 162 
change was dichotomized into, ‘dispensed fewer’ or ‘dispensed more’, CSPs. The primary 163 
independent variable of interest was whether or not respondents indicated that INSPECT was a 164 
factor leading to their dispensation change.  Backward elimination was used to fit the model and 165 
to include all conceptually relevant independent variables in order to reduce possibility of a 166 
suppressor effect within the model.16  These variables were removed one by one and the 167 
procedure determined the contribution of each variable at each step.  All significant independent 168 
variables identified through this process were retained in the multiple regression analysis.  The 169 
same process was followed for the other two (2) outcome measures.  Refused dispensation, a 170 
binary variable, was analyzed in similar fashion using a binary logistic regression model to 171 
determine if reported use of INSPECT increased the likelihood of a pharmacist reporting at least 172 
one (1) refusal in the past 12 months.   173 
The last outcome measure, annual refusals, was analyzed to determine to what degree 174 
various practice characteristics, such as the frequency of INSPECT use, influences a 175 
pharmacist’s reported number of annual CSP refusals. The annual refusal data were categorized 176 
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into five (5) groups due to a non-normal distribution of the data which was revealed by execution 177 
of Kolmogorov-Smirnov test for normality (D=.24, P<.01).   As a result, these data were 178 
analyzed using a multiple ordinal logistic regression model. 179 
RESULTS 180 
Demographics 181 
The majority of respondents reported working in an outpatient setting (73.9%) compared 182 
to an inpatient setting as reported in Table 3.  There were more male (54.4%) then female 183 
respondents.  The mean age of respondents was 46.9 years of age.  The average years practicing 184 
was 20.8 years with more than half the respondents having 20 or more years of experience.  185 
Nearly all respondents reported having heard of INSPECT (94.3%) prior to receiving the survey.  186 
However, only 71.8% of the respondents who had heard of INSPECT reported using it.  187 
Change in Dispensation Practice of CSPs 188 
A total of 506 (37.6%) respondents indicated that they had changed their dispensing 189 
practice related to CSPs in the last 12 months. Of those who reported changing their dispensing 190 
practices, significantly more respondents (74.7%) reported a change to dispense fewer CSPs (X2 191 
= 183.0, p < .0001) compared to those who reported a change to dispense more CSPs.  192 
Respondents were also asked to report on the factors that led to the dispensation change.  The 193 
frequencies for the various factors leading to a dispensation change are provided in Table 4. The 194 
most frequently reported factors leading to a change in dispensing practice of CSPs were:  195 
(1) New professional practice standards and protocols 196 
(2) INSPECT providing greater access to patient prescription drug history 197 
(3) Increased professional awareness of risks, benefits, and other solutions.   198 
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As illustrated by these data, in table 4, more than half (53%) of pharmacists reporting a change in 199 
their dispensing practice attribute the change to INSPECT increasing access to patient 200 
prescription drug history.  Pharmacists were 6.4 times more likely to report a dispensation 201 
change to dispense fewer CSPs, if they also reported that increased access to patient prescription 202 
drug history through INSPECT was a factor leading to the change (OR = 6.4, 95% CI, 3.437 – 203 
11.862).  204 
Refused Dispensation of CSPs 205 
Significant variations in pharmacists’ decision to refuse to dispense a CSP existed within 206 
several practice and demographic characteristics including pharmacy setting, gender, training 207 
period, and use of INSPECT.  These data are provided in Table 5.  Outpatient pharmacists were 208 
21 times more likely to have refused to dispense a CSP compared to inpatient pharmacists (OR = 209 
20.9, 95% CI, 11.007 – 39.836).  Practitioners who trained in Cohort 1 were 2.4 times more 210 
likely to refuse to dispense a CSP compared to pharmacists trained in Cohort 3 (OR = 2.4, 95% 211 
CI, 1.343 – 4.218).  In other words, pharmacists trained after full implementation of the 212 
Accreditation Council for Pharmacy Education (ACPE) new accreditation and standards 213 
guidelines were more confident in refusing dispensing a CSP. Also, male pharmacists were 2.5 214 
times more likely to have reported refusing dispensation of a CSP in the past 12 months 215 
compared to females (OR = 2.5, 95% CI, 1.454 – 4.204).  Multiple logistic regression analysis 216 
indicated that pharmacists who reported using INSPECT were significantly more likely to have 217 
refused dispensation of a CSP compared to practitioners who did not use INSPECT (OR = 2.2, 218 
95% CI, 1.339 – 3.693).   219 
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Annual Refusals of CSPs 220 
Pharmacists may be more likely to refuse to dispense a CSP if using INSPECT, but the 221 
study aimed to further examine the relationship between consistent use of INSPECT and the 222 
magnitude of refusals reported by pharmacists. Table 6 provides the mean number of refusals 223 
based on key practice and demographic characteristics.  Pharmacists who reported never using 224 
INSPECT only refused to dispense 6.9 CSPs on average per year.  However, pharmacists who 225 
have completely integrated INSPECT into their professional practice and report always using the 226 
program, refused to dispense 24.8 CSPs on average per year. The multiple logistic regression 227 
model demonstrated that practitioners who reported using INSPECT “Periodically” or “At every 228 
visit” were statistically more likely to refuse to dispense more CSPs than pharmacists who 229 
reported never checking INSPECT (ORperiodically = 3.0, 95% CI, 1.351 – 6.763; OReveryvisit = 3.3, 230 
95% CI, 1.307 – 8.465). 231 
DISCUSSION 232 
Reducing prescription drug abuse in the United States is a multifaceted and intricate 233 
process that must be addressed from multiple perspectives.  One of the major driving forces 234 
responsible for prescription drug abuse is the rise in opioid prescribing rates throughout the U.S.  235 
The number of opioid prescriptions dispensed by retail pharmacies has increased consistently 236 
since 1991.17   General prescribing practices, high-volume prescribing, or even pill mills directly 237 
influence the increasing rates of opioid prescriptions being dispensed by retail pharmacies.17   238 
Regardless of the original source of these prescriptions, pharmacists share responsibility with the 239 
prescriber to ensure that these prescriptions are issued for a valid medical purpose.   240 
DEA regulation 21 C.F.R. 1306.04 defines corresponding responsibility and understands 241 
that pharmacists play an integral role in preventing the diversion of controlled substances.6  242 
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Under this regulation, pharmacists are instructed to “exercise their professional judgment to 243 
determine whether a prescription for a controlled substance was issued for a legitimate reason”.5  244 
Unfortunately, pharmacists frequently find themselves in precarious situations where they must 245 
determine if a controlled substance prescription was issued for a legitimate medical purpose by a 246 
practitioner acting in the usual course of professional practice.  Many times pharmacists in these 247 
situations have few resources and have limited access to patient information needed to make 248 
sound clinical-decisions. Maxwell et al., suggested that the limited access to patient information 249 
fundamentally hampers pharmacists’ abilities to make informed clinical-decisions.18   250 
The Department of Health and Human Services (DHHS) identified ‘clinical practice 251 
tools’, such as PDMPs, as 1 of 8 primary domains necessary to preventing prescription drug 252 
abuse.17   PDMPs may alleviate, to some degree, pharmacists’ lack of access to patient 253 
information. One of the primary purposes of PDMPs is to increase access to patient prescription 254 
drug histories, which are critical to making informed clinical-decisions and exercising good 255 
professional judgment.  According to the PDMP Center for Excellence, evidence continues to 256 
suggest that PDMPs are valuable tools for providers that ultimately may improve clinical 257 
decision-making and help reduce diversion of controlled substances.10   258 
This study set out to explore the use of Indiana’s prescription drug monitoring program as 259 
a support tool for improving clinical decision-making among pharmacists.  It also examined the 260 
influence PDMPs have on CSP dispensing behaviors. The results from this study suggest that the 261 
use of INSPECT may lead to a reduction in CSP dispensing, which is illustrated by an increased 262 
likelihood of pharmacists to modify their dispensing practice to dispense fewer CSPs as a result 263 
of increased access to a patient’s drug history.   This also suggests that PDMPs may, in fact, 264 
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provide more information to pharmacists that may help to inform and support their professional 265 
judgment to exercise corresponding responsibility.  266 
Not only did the use of INSPECT result in a reported reduction of dispensed controlled 267 
substances by pharmacists, but pharmacists were more likely to report refusing to dispense CSPs 268 
if they used INSPECT.  In this regard, our data suggest that the use of INSPECT may facilitate 269 
pharmacists to exercise corresponding responsibility.  We suspect that this is due to PDMPs 270 
providing greater access to patient information that serves as evidence to support their 271 
professional judgment to refuse to dispense a CSP in the event they are unable to resolve an 272 
identified red flag while processing a prescription. 273 
Additionally, more consistent use of INSPECT was significantly more likely to result in a 274 
higher number of refusals to dispense controlled substances by a pharmacist. Practitioners who 275 
reported using INSPECT periodically or at every visit were significantly more likely to refuse to 276 
dispense a CSP as compared to pharmacists who reported never using INSPECT.  This finding 277 
further exemplifies the notion that the integration and consistent use of INSPECT in pharmacy 278 
practice may provide pharmacists with the information necessary to be confident in their 279 
professional judgment and clinical decisions.  280 
The findings from this study are consistent with findings from previous studies which 281 
concluded that PDMPs increase a pharmacist’s level of confidence in their clinical decisions and 282 
professional judgment.13, 14  This study adds a unique dimension to the growing body of literature 283 
surrounding prescription drug diversion and abuse, as the majority of current literature examines 284 
the overall effectiveness of PDMPs and the role of prescribers in reducing drug diversion and 285 
prescription drug abuse.10  Less research is available regarding the impact PDMPs have on 286 
pharmacists’ dispensing practice relating to CSPs. This study was one of the first known studies 287 
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to quantify pharmacists’ professional judgment to refuse to dispense a CSP by examining the 288 
number of refusals reported by pharmacists.  289 
Study Limitations 290 
 As PDMPs are now implemented in 49 states, there is a need for research that is capable 291 
of evaluating their effectiveness in reducing drug diversion throughout the country.  Many states 292 
have started to evaluate these programs, but there are some limitations.  The primary limitation 293 
to this study was response bias.  Issues of drug diversion and prescribing or dispensing practices 294 
are considered to be controversial by many providers.  Pharmacists may be hesitant to disclose 295 
information regarding dispensing practices due to fear of legal ramifications.  It is likely that 296 
response bias may result in an overestimate of pharmacists reported number of refusals of CSPs.  297 
However, the IPLA INSPECT Knowledge and Use Survey was administered as an anonymous 298 
survey to help limit the potential response bias.  Furthermore, the response rate for the survey 299 
was low and may be a limitation to the study.  However, measures were taken to compare 300 
Indiana’s pharmacist workforce to the study’s sample in order to determine if the sample was 301 
similar to that of Indiana’s pharmacist workforce.  Lastly, the study was conducted within one 302 
state, Indiana.  Therefore the generalizability of these findings to other states may be a limitation.  303 
In light of these limitations, the study findings should still be considered due to their implications 304 
and consistency with previous literature.   305 
CONCLUSION 306 
The Drug Enforcement Agency states that enforcement action against pharmacists is 307 
most likely to occur when pharmacists fail to exercise corresponding responsibility.5 308 
Unfortunately, the interpretation of what constitutes “exercising corresponding responsibility” is, 309 
to some degree, up for discussion.  The DEA does indicate that pharmacists must identify and 310 
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resolve red flags prior to dispensing a controlled substance.  Red flags arise as a result of pattern 311 
prescribing, fraudulent prescriptions, paying cash, or geographic anomalies, to name a few.  Yet, 312 
lack of access to complete patient information as well as segmented relationships between 313 
pharmacists and physicians make resolution of red flags a time consuming and tedious task.  314 
These challenges may actually make exercising corresponding responsibility for pharmacists 315 
quite difficult.  However, this study suggests that pharmacists who consistently use prescription 316 
drug monitoring programs in their pharmacy practice are over 3 times more likely to refuse 317 
controlled substance prescriptions as compared to those pharmacists who do not use a PDMP as 318 
a clinical practice tool.  Implementing policies, strategies, and practices that support pharmacists 319 
in fulfilling their duty to “exercise his/her independent judgment when determining whether a 320 
prescription was issued for a legitimate medical purpose by a practitioner acting in the usual 321 
course of professional practice”5, are vital to reducing diversion of prescription drugs. Future 322 
research should focus on understanding the barriers and challenges to successful integration of 323 
PDMPs in pharmacy practice.  324 
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TABLES & FIGURES 334 
 335 
  336 
Table 1 
Operational definitions for study outcome measures 
Outcome Measure Operational Definition 
Dispensation Change Dispensation change is binary variable that identifies if a 
pharmacist reported a change in dispensing practice to 
dispense fewer or more controlled substances in the past 12 
months. (dispense fewer=1, dispense more=0) 
 
Refused Dispensation Refused dispensation is a binary variable that indicates if a 
pharmacist reported refusing to dispense a controlled 
substance within the past 12 months. (Yes=1, No=0) 
 
Annual Refusals A pharmacist’s total number of reported refusals to dispense a 
controlled substance within the past 12 months was an ordinal 
categorical variable with 5 categories.  
      Category 1:    < 1 refusals per year 
      Category 2:    1-5 refusals per year 
      Category 3:  6-10 refusals per year 
      Category 4: 11-20 refusals per year 
      Category 5:   > 20 refusals per year 
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Table 2 
Parameters used to determine training period cohorts 
Training Period Description 
Cohort 1 
Pharmacists trained after complete transition to the PharmD as the sole 
entry degree for the pharmacist profession and full implementation of 
ACPE’s1 new accreditation standards. 
Cohort 2 
Pharmacists trained during the transition to the Doctor of Pharmacy 
(PharmD) as the sole professional practice degree for pharmacy in the 
United States and after the adoption of ACPE’s new accreditation 
standards in 1997. 
Cohort 3 
Pharmacists trained prior to the adoption of ACPE’s1 Implementation 
Procedures for Accreditation Standards and Guidelines for the 
Professional Program in Pharmacy Leading to the Doctor of Pharmacy 
Education.  New accreditation standards and guidelines were adopted in 
June of 1997.  
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Table 3 
Descriptive statistics for key demographic and practice characteristics of study sample 
 
 IPLA INSPECT  Survey Sample 
2012 Indiana Pharmacist  
Workforce Data  
Demographic Characteristic N (%) N (%) Statistic 
Age (years) Mean ± SD, 46.9 ± 13.7 Mean ± SD, 46.3 ± 12.4 P > .05 
Years Practicing Mean ± SD, 20.8 ± 14.0 Mean ± SD, 20.3 ± 12.9 P > .05 
Gender   X2 = .417, P > .05 
     Female 833 (54) 4963 (58)  
     Male 699 (46) 3645 (42)  
Race/Ethnicity (n=1523)a    
     White/non-Hispanic 1,408 (93)   
     Asian American/ Pacific Islander 52 (3)   
     Black/non-Hispanic 28 (2)   
     American Indian/ Alaska Native 6 (0)   
     Hispanic/Latino 15 (1)   
Training Period    
     Cohort 1 412 (27)   
     Cohort 2 483 (31)   
     Cohort 3 630 (41)   
Pharmacy Setting    
     Inpatient 353 (26)   
     Outpatient 1,000 (74)   
Heard of INSPECT    
     Yes 1,469 (94)   
     No 88 (6)   
Used INSPECT    
     Yes 1,043 (72)   
     No 410 (28)   
 Frequency of INSPECT    
     At every visit 73 (8)   
     Periodically 799 (78)   
     Never 39 (4)   
 341 
  342 
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Table 4 
Frequency of factors which led to a change in dispensing practice of controlled substance 
prescriptions 
What factors led you to change your dispensing practices? (N=497) N (%) 
New professional practice standards and protocols 276 (56) 
INSPECT providing greater access to patient prescription drug history 263 (53) 
Increased professional awareness of risks, benefits, and other solutions 249 (50) 
Increased state or federal guidelines and recommendations 193 (39) 
Change in my patient mix 121 (24) 
I am afraid of legal ramifications 103 (21) 
Increased law enforcement activity 65  (13) 
Increased referrals from other physicians/providers for treatment of chronic pain 
patients 63  (13) 
Increased patient awareness of risks and benefits 38   (8) 
Increased referrals from other physicians/providers for treatment of acute 
(surgical/traumatic/short-term) pain patients 37   (7) 
Other 72  (15) 
 343 
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Table 5 
Pharmacists reported refusal to dispense a controlled substance prescription by key 
demographic and practice characteristics 
Characteristic Refused to Dispense 
Did Not 
Refuse to 
Dispense 
Total 
Responses X
2 P-Value 
 N (%) N (%)    
Pharmacy Type   1,222 233.1 < .0001 
     Inpatient 217 (70) 94 (30)    
     Outpatient 896 (98) 15 (2)    
Gender   1,305 12.6 0.0004 
     Female 639 (88) 85 (12)    
     Male 546 (94) 35 (6)    
Training Period   1,337 13.0 0.0015 
     Cohort 1 330 (88) 46 (12)    
     Cohort 2 386 (90) 45 (10)    
     Cohort 3 500 (94) 30 (6)    
Have you ever used INSPECT?   1,254 57.2 < .0001 
     Yes 890 (95) 51 (5)    
     No 252 (81) 61 (20)    
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Table 6 
Pharmacists reported annual refusals to dispense controlled 
substance prescriptions by key demographic and practice 
characteristics 
Characteristic Mean (SD) Statistic P Value 
Pharmacy Type  -10.36 < .0001 
     Inpatient 2.6  (5.3)   
     Outpatient 21.2 (25.6)   
Gender  -2.01 0.045 
     Female 15.7 (22.7)   
     Male 18.6 (25.5)   
Training Period  3.21 0.041 
     Cohort 1 19.4 (26.2)   
     Cohort 2 18.4 (25.2)   
     Cohort 3 15.5 (22.3)   
Frequency of INSPECT Use  5.68 0.004 
     Never 6.9 (13.1)   
     Periodically 18.6 (23.9)   
     At Every Visit 24.8 (27.3)   
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